TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for B-cell mediated diseases and autoimmune disorders. The company's flagship commercial product is BRIUMVI (ublituximab-xiiy), a glycoengineered anti-CD20 monoclonal antibody approved by the FDA for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS).
The company generates the vast majority of its revenue from the commercial sale of BRIUMVI in the United States. In 2025, TG Therapeutics reported total revenues of approximately $616 million, driven primarily by U.S. net product sales of BRIUMVI, as well as revenue from an ex-U.S. commercialization agreement with Neuraxpharm Pharmaceuticals, which launched the product in Europe.
Beyond its commercial operations, TG Therapeutics maintains an active clinical development pipeline. Key pipeline initiatives include the development of a subcutaneous formulation of ublituximab to offer alternative dosing options for patients, as well as azer-cel, an investigational allogeneic (off-the-shelf) CAR T-cell therapy being evaluated for progressive forms of multiple sclerosis and other autoimmune conditions. The company's business model relies on advancing these proprietary biologic therapies through clinical trials, securing regulatory approvals, and driving market penetration in the highly competitive neurology and immunology therapeutic areas.
